MyFinsight
Home
Blog
About
Cash and cash
equivalents
$677,911K
(-9.49%↓ Y/Y)
Accounts receivable, net
$254,484K
(231.07%↑ Y/Y)
Prepaid expenses and
other current assets
$65,652K
(8.98%↑ Y/Y)
Inventories
$52,842K
(189.12%↑ Y/Y)
Marketable securities
$42,249K
(432.17%↑ Y/Y)
Total current assets
$1,093,138K
(19.83%↑ Y/Y)
Equity method
investments
$55,095K
Intangible assets, net
$26,641K
(-9.73%↓ Y/Y)
Other assets
$20,120K
(11.13%↑ Y/Y)
Operating lease
right-of-use assets
$17,079K
(176.09%↑ Y/Y)
Property and equipment,
net
$5,226K
(-14.43%↓ Y/Y)
Accumulated deficit
-$4,137,453K
(-20.08%↓ Y/Y)
Treasury stock, at cost
7,597,172 shares as of june...
$533,279K
Accumulated other
comprehensive income (loss)
-$7K
(-800.00%↓ Y/Y)
Total assets
$1,217,299K
(12.69%↑ Y/Y)
Total bridgebio
stockholders deficit
-$2,515,215K
(-40.68%↓ Y/Y)
Additional paid-in capital
$2,155,318K
(8.81%↑ Y/Y)
Common stock, 0.001 par
value 500,000,000...
$206K
(4.04%↑ Y/Y)
Total liabilities,
redeemable convertible...
$1,217,299K
(12.69%↑ Y/Y)
Total stockholders
deficit
-$2,504,875K
(-40.88%↓ Y/Y)
Redeemable convertible
noncontrolling interests
-$1,018K
(-128.76%↓ Y/Y)
Noncontrolling interests
$10,340K
(4.59%↑ Y/Y)
Total liabilities
$3,723,192K
(30.24%↑ Y/Y)
Total current
liabilities
$890,648K
(406.47%↑ Y/Y)
Deferred royalty
obligations, net
$879,374K
(8.04%↑ Y/Y)
2027 notes, 2029
notes, 2031 notes and...
$741,918K
2027 notes, 2029
notes, 2031 notes and...
$620,087K
2027 notes, 2029
notes, 2031 notes and...
$565,528K
Operating lease
liabilities, net of current...
$14,973K
(272.00%↑ Y/Y)
Deferred revenue, net of
current portion
$10,424K
(-28.93%↓ Y/Y)
Other long-term
liabilities
$240K
(-55.96%↓ Y/Y)
Unamortized debt discount
and issuance costs
$48,871K
2027 notes, net
$547,955K
Other current
liabilities
$192,186K
(191.56%↑ Y/Y)
Accrued research and
development liabilities
$64,468K
(106.00%↑ Y/Y)
Accrued compensation
and benefits
$49,976K
(34.39%↑ Y/Y)
Accounts payable
$27,202K
(4.09%↑ Y/Y)
Deferred revenue,
current portion
$5,546K
(-47.38%↓ Y/Y)
Operating lease
liabilities, current portion
$3,315K
(-30.68%↓ Y/Y)
Carrying value of
deferred royalty...
$912,536K
Fair value of
embedded derivative...
$15,709K
Funding Agreement
$15,709K
(-96.97%↓ Y/Y)
Back
Back
Balance Sheet
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)
source: myfinsight.com